|
|
|
| Application of arterial interventional chemotherapy and embolization in advanced-stage epithelial ovarian cancer |
| Department of Gynecology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015 |
|
| Cite this article: |
|
YU Jiangtao,ZHENG Feiyun,WANG Qiang.. Application of arterial interventional chemotherapy and embolization in advanced-stage epithelial ovarian cancer[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2015, 45(1): 50-50.
|
|
|
|
Abstract Objective: To explore the signicance of the arterial interventional chemotherapy and embolization in the treatment of advanced-stage epithelial ovarian cancer. Methods: From December 1, 1999 to May 31, 2012, 100 patients of epithelial ovarian cancer in advanced-stage were admitted and all of them had cytoreductive surgery in our hospital. According to whether or not to accept the arterial interventional chemotherapy and embolization, patients of advanced-stage epithelial ovarian cancer were divided into two groups before cytoreductive surgery. Those were the arterial interventional chemotherapy and embolization group (the treated group) and primary cytoreductive surgery group (the control group). There were 27 cases in the treated group which had 1-2 courses of the arterial interventional chemotherapy and embolization before operation. While the other 73 cases in the control group had initial cytoreductive surgery. The results were analyzed retrospectively, comparing the two groups of patients with clinical indicators, related prognostic factors and the cumulative survival rate. Results: Comparison of factors between the two groups showed that the treatment group with high grade, stage late accounts for the proportion to be high. However, the rates of optimal cytoreductive surgery in the treated group were higher than that of the control group. There was no statistically significant difference between the two groups (P>0.05). Multivariate survival analysis showed that pathological staging and operation satisfaction were independent prognostic factors affecting overall survival rates for patients (P=0.010 and P=0.011). The 3-year and 5-year cumulative survival rates were 64% and 48% in the treated group, while 62% and 40% in the control group. There was no statistically significant difference between the two groups (P>0.05). Coclusions: Patients of advanced-stage epithelial ovarian cancer who can not to achieve optimal cytoreductive surgery should receive preoperative arterial interventional chemotherapy and embolization. It may improve the success rate of the operation, but can not improve the overall cumulative survival rate.
|
|
Received: 21 January 2014
|
| |
|
|
|
[1] 高永良, 朱笕青. 卵巢癌的靶向治疗现状与展望[J]. 肿瘤研究与临床, 2011, 23(9): 577-580.
[2] Lee SJ, Kim BG, Lee JW, et al. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery[J]. J Obstet Gynaecol Res, 2006, 32(1): 99-106.
[3] 曹泽毅. 中华妇产科学[M]. 北京: 人民卫生出版社, 2011: 717-726.
[4] 杨超, 金泳海, 邹建伟, 等. 术前介入性化疗栓塞治疗卵巢癌63例疗效评估[J]. 介入放射学杂志, 2011, 20(5): 385-388.
[5] Bristow RE, Chi DS. Platinum-based neoadjuvant chemo-therapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis[J]. Gynecol Oncol, 2006, 103(3): 1070- 1076.
[6] 李伟大, 陈艳, 王煜晅, 等. 卵巢子宫内膜样癌的CT、MRI诊断与病理分析[J]. 温州医科大学学报, 2014, 44(3): 209-212.
[7] 金慧佩, 赵雅萍, 黄品同, 等. 超声造影在妇科附件良恶性肿块诊断中的应用[J]. 温州医学院学报, 2009, 39(5): 487-489.
[8] Williams C, Simera I, Bryant A. Tamoxifen for relapse of ovarian cancer[J]. Cochrane Database of Syst Rev, 2010(3): CD001034.
[9] Ma L, liu X, Tian JH, et al. Gemcitabine for platinum-resistant or recurrent ovarian cancer[J]. Cochrane Database of Syst Rev, 2010(2): CD008254. |
|
|
|
